The following is a summary of “Racial disparities in patients with proliferative diabetic retinopathy treated with pars plana vitrectomy in an underserved population,” published in the April 2025 ...

A single intravitreal injection of UBX1325 (foselutoclax) was shown to be safe in patients with diabetic macular edema. The ...

New research reveals UBX1325's potential to significantly improve vision in diabetic macular edema patients, offering hope ...

Diabetic retinopathy (DR) is a common complication associated with diabetes mellitus, resulting in significant visual impairment in middle-aged and elderly individuals. The advanced stages of DR, ...

High blood pressure (hypertension) can lead to many complications of diabetes, including diabetic eye disease and kidney disease, or make them worse. Most people with diabetes will eventually have ...

Credit: SUPERMAO/Shutterstock. Vantage Biosciences has dosed the first subject in the randomised Phase II trial of oral therapy VX-01 to treat non-proliferative diabetic retinopathy (NPDR). The ...

As the burden of diabetes continues to rise in India, diabetic retinopathy has emerged as one of its most debilitating complications—often leading to irreversible vision loss if left undiagnosed.

They shed light on the critical aspects of diabetic retinopathy and its far-reaching implications. The statistics paint a troubling picture. Recent studies reveal that just 7% of Indians maintain ...

A team of Chinese researchers reported that fasting C-peptide (FCP) has a complicated relationship with the development of diabetic retinopathy (DR). Below a specific threshold, FCP exerts a ...

It is currently scaling an AI solution that it began piloting in 2022: Digital Diagnostics’ AI system that autonomously diagnoses diabetic retinopathy. The system, called the LumineticsCore ...

Diabetes during pregnancy is associated with an increased risk of neuro-developmental disorders (NDDs) like autism, according to a meta-analysis published in The Lancet Diabetes and Endocrinology.

Mounjaro, a new treatment for Type 2 diabetes and obesity, has been launched in India after CDSCO approval. The drug, developed by Eli Lilly and Company, targets both GIP and GLP-1 receptors ...